Losartan Liquid Formulation Patent, Scienture LLC, Apr 21
Summary
The USPTO granted patent US12605365B2 to Scienture, LLC on April 21, 2026. The patent covers stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts for oral administration, along with powder compositions for reconstitution and methods of treating subjects in need of losartan. The patent contains 20 claims and is classified under CPC A61K 31/4178 and A61K 9/10.
“The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration.”
About this source
GovPing monitors USPTO Patent Grants - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 26 changes logged to date.
What changed
The USPTO granted patent US12605365B2 to Scienture, LLC for stable, liquid pharmaceutical compositions of losartan or salts thereof for oral administration. The patent also covers powder compositions for reconstitution and methods of treating patients requiring losartan therapy. Assignees and competitors in the cardiovascular pharmaceutical space should assess this IP position for potential licensing or design-around opportunities.
Competitors developing liquid formulations of losartan or related angiotensin II receptor antagonists may face freedom-to-operate considerations. The patent's 20 claims provide Scienture with exclusivity over the specific compositions and methods described through at least the patent's expiration term.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Losartan liquid formulations and methods of use
Grant US12605365B2 Kind: B2 Apr 21, 2026
Assignee
Scienture, LLC
Inventors
Bhavya Teja Kolla, Rahul Surana, Suketu Sanghvi, Jigar Bhatt
Abstract
The present disclosure relates to stable, liquid pharmaceutical compositions of losartan or pharmaceutically acceptable salts thereof for oral administration. The present disclosure further provides powder compositions for reconstitution to provide a liquid formulation. In further aspects, the present disclosure relates to processes for preparation of such pharmaceutical compositions, and methods of treating a subject in need of losartan by administration of a formulation described herein.
CPC Classifications
A61K 31/4178 A61K 9/10
Filing Date
2022-12-05
Application No.
18061819
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.